Showing 2421-2430 of 3223 results for "".
- France First in EU to Reimburse Hoya MiYOSMART Lens for Childhood Myopiahttps://modernod.com/news/france-first-in-eu-to-reimburse-hoya-miyosmart-lens-for-childhood-myopia/2482856/France will begin reimbursing Hoya Vision Care’s MiYOSMART myopia control spectacle lenses for eligible children starting July 1. This move makes France as the first country in the European Union to provide public coverage for the lenses.
- Sightview Appoints Tycene Fritcher as CEOhttps://modernod.com/news/sightview-appoints-tycene-fritcher-as-ceo/2482850/Ophthalmic Electronic health record (EHR) provider Sightview announced that Tycene Fritcher has been appointed Chief Executive Officer. Ms. Fritcher brings more than two decades of leadership experience in healthcare IT, including tenures at Nextech, Avizia, and Am
- Amneal Receives FDA Approval for Prednisolone Acetate Ophthalmic Suspensionhttps://modernod.com/news/amneal-receives-fda-approval-for-prednisolone-acetate-ophthalmic-suspension/2482847/Amneal Pharmaceuticals announced the FDA approval of prednisolone acetate ophthalmic suspension 1% sterile, which references Pred Forte (Allergan, an AbbVie company). Launch of the product is planned for the third quarter of 2025. Prednisolone acetate ophthalmic suspension USP 1% i
- Hoya Presents New Clinical Evidence on Myopia Management and Launch of visuReal MoveAI Kids Modulehttps://modernod.com/news/hoya-presents-new-clinical-evidence-on-myopia-management-and-launch-of-visureal-moveai-kids-module/2482810/Hoya Vision Care presented its latest clinical evidence at the 16th Annual European Academy of Optometry and Optics (EAOO) conference in Ljubljana, Slovenia. The company also unveiled its new visuReal MoveAI Kids Module, an AI-powered video centration syste
- Aurion Makes Leadership Announcementshttps://modernod.com/news/aurion-makes-leadership-announcements/2482757/Aurion Biotech announced the appointments of Edward J. Holland, MD, as Chief Medical Officer, and Eris P. Jordan, OD, as Chief Development Officer. Aurion is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema seconda
- Glaukos to Present Multiple Scientific Abstracts at ASCRShttps://modernod.com/news/glaukos-to-present-multiple-scientific-abstracts-at-ascrs/2482751/Glaukos announced that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 25-28, 2025 in Los Angeles. Glaukos will be exhibiting onsite at booth #2227. Glaukos is also spo
- FDA Denies Regeneron's BLA for Extended Dosing Intervals for Eylea HDhttps://modernod.com/news/fda-denies-regenerons-bla-for-extended-dosing-intervals-for-eylea-hd/2482747/Regeneron announced that the FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved indication
- Nordic Pharma Receieves CE Mark Approval for Lacrifill Canalicular Gelhttps://modernod.com/news/nordic-pharma-receieves-ce-mark-approval-for-lacrifill-canalicular-gel/2482729/Nordic Group, the parent company of Nordic Pharma, announced that its dry eye therapy Lacrifill has received CE mark approval. This regulatory milestone, which Nordic says was achieved several months ahead of schedule, allows Nordic Pharma to introduce Lacrifill across Europea
- Hoya Launches VisuPro Advanced Focus Spectacle Lenses for Patients Experiencing Early Symptoms of Presbyopiahttps://modernod.com/news/hoya-launches-visupro-advanced-focus-spectacle-lenses-for-patients-experiencing-first-symptoms-of-presbyopia/2482724/Hoya has launched its VisuPro All Day and VisuPro Flex advanced focus spectacle lenses, which are designed to help people in their late 30s to mid-40s that are beginning to experience presbyopia. As people enter this age group, they may begi
- Pantheon Vision Announces Partnership with EyeDeal Medical to Develop Bioengineered Corneal Implanthttps://modernod.com/news/pantheon-vision-announces-partnership-with-eyedeal-medical-to-develop-bioengineered-corneal-implant/2482719/Pantheon Vision today announced a partnership with manufacturer EyeDeal Medical to develop an artificial, bioengineered corneal implant. Their goal, the company states, is to eliminate corneal blindness by removing the need for human donor corneal tissue. Corneal blindness is the